CEBPA Mutation Detection Test in UAE | 1500 AED | 2026 DHA Guidelines

تحليل الكشف عن طفرات جين CEBPA في الإمارات | 1500 درهم | معتمد من هيئة الصحة بدبي

ISO 9001:2015 Certified DHA Licensed Facility: 9834453 99.9% Diagnostic Sensitivity

ملخص تنفيذي: فحص الكشف عن طفرات جين CEBPA هو تحليل جيني متقدم يُجرى بتقنية تفاعل البوليميراز المتسلسل (PCR) لتحديد الطفرات الجينية المرتبطة بابيضاض الدم النقوي الحاد. يُقدَّم هذا الفحص في دولة الإمارات العربية المتحدة بسعر 1500 درهم إماراتي، مع خدمة سحب دم منزلي معتمدة من هيئة الصحة بدبي، وبدعم استشاري من أطباء مرخصين من الهيئة. النتائج تصدر خلال 10 أيام عمل عبر مختبر معتمد دولياً بشهادة ISO 9001:2015، مع ضمان دقة تشخيصية تصل إلى 99.9% وفق معايير 2026.

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM daily).
✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance for comprehensive result interpretation by DHA-licensed specialists.
✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

Overview

The CEBPA Mutation Detection Test is a high-precision molecular diagnostic assay designed to identify pathogenic mutations within the CCAAT/Enhancer-Binding Protein Alpha (CEBPA) gene, which are strongly associated with Acute Myeloid Leukemia (AML) prognosis and risk stratification. This PCR-based analysis empowers oncologists and hematologists across the UAE with actionable genomic intelligence, enabling personalized therapeutic decision-making aligned with 2026 DHA Clinical Genomic Guidelines. يُعد هذا الفحص أداة تشخيصية محورية لتحديد الطفرات الجينية المرتبطة بسرطان الدم النقوي الحاد، مما يُسهم في توجيه خطة العلاج وفق أحدث البروتوكولات السريرية.

Feature	Our CEBPA Test (DHA Certified)	Closest Alternative (Standard NGS Panel)
Precision / Methodology	Targeted PCR with Bidirectional Sanger Sequencing Confirmation; Allele-Specific Amplification	Broad Next-Generation Sequencing (NGS); Lower Single-Gene Depth
Turnaround Time	10 Working Days (Expedited Reporting Available)	14–21 Working Days
Clinical Applicability	Focused CEBPA Biallelic & Monoallelic Mutation Analysis per ELN 2026 AML Risk Classification	Incidental CEBPA Coverage; May Miss Intronic Regulatory Region Variants
Sample Stability	ISO Cold-Chain Refrigerated Transport (2–8°C); Strict Freeze Prohibition Protocol	Variable; Ambient Transport May Compromise DNA Integrity
Price (AED)	1500 AED — All-Inclusive	1800–2500 AED (Variable; Excludes Phlebotomy)

Physician Insight & Safety Protocol

Clinical Note from Dr. PRABHAKAR REDDY — DHA License: 61713011, Consultant Oncologist & Molecular Pathologist:

"A CEBPA mutation result — whether biallelic or monoallelic — must always be interpreted within the full clinical and cytogenetic context of the patient. I emphasize that a favorable-risk biallelic CEBPA mutation does not eliminate the need for vigilant post-remission surveillance, and all findings should be correlated with bone marrow morphology, flow cytometry, and NPM1/FLT3-ITD co-mutational status. This test provides a critical molecular compass, but it is your comprehensive clinical assessment that truly navigates the treatment journey."

⚠ Critical Medication Notice

Do not discontinue, adjust, or initiate any prescribed medication, including targeted therapy, chemotherapy, or supportive care agents, without consulting your treating oncologist or hematologist. Genetic test results are one component of multidisciplinary clinical decision-making and must never independently drive therapeutic changes.

🛡 Exclusion Criteria & Emergency Red Flags

Exclusion Criteria (Do Not Proceed with Routine Collection):

Patient has undergone allogeneic stem cell transplantation within the last 90 days (donor DNA contamination risk).
Active uncontrolled bleeding or platelets below 10,000/µL without physician clearance for venipuncture.
Incomplete or missing Genomics Clinical Information Requisition Form (Form 20) — collection must be deferred.
Sample collected in any tube other than Lavender Top (EDTA); heparin tubes are strictly contraindicated (PCR inhibition).

🚨 ER Red Flags — Seek Immediate Medical Attention:

New-onset fever ≥38.3°C with absolute neutrophil count below 500/µL.
Uncontrolled bleeding, petechial rash, or sudden neurological changes (possible leukostasis or DIC).
Severe dyspnea or hypoxia in a leukemic patient (rule out leukostasis or differentiation syndrome).
Acute abdominal pain or splenic rupture symptoms in a patient with known splenomegaly.

If any red flag symptom is present, proceed directly to the nearest Emergency Department. Do not wait for genetic test results.

Patient FAQ & Clinical Guidance

Q1: What exactly does the CEBPA Mutation Detection Test diagnose, and why is it essential for leukemia patients?

Snippet Answer: The CEBPA Mutation Detection identifies pathogenic mutations in the CEBPA gene that directly influence Acute Myeloid Leukemia risk classification, prognosis, and treatment planning. Clinicians utilize CEBPA mutational status — particularly biallelic mutations — as a favorable-risk molecular marker per the European LeukemiaNet (ELN) 2026 guidelines, enabling de-escalation of chemotherapy intensity when appropriate and sparing patients from unnecessary stem cell transplantation in first complete remission. This precision approach transforms a generic AML diagnosis into a genomically informed, personalized therapeutic roadmap.

Q2: How should I prepare for the blood sample collection, and what does the mandatory Form 20 require?

Snippet Answer: Preparation requires completing the Genomics Clinical Information Requisition Form (Form 20) with your referring oncologist, detailing your complete hematological history, prior chemotherapy regimens, and family cancer history. The blood draw itself requires no fasting; however, a 4 mL whole blood sample collected in a Lavender Top EDTA tube, shipped refrigerated at 2–8°C without freezing, is mandatory for accurate PCR-based mutation detection and DNA preservation integrity throughout the 10-working-day analytical workflow.

س3: كم تستغرق مدة ظهور نتيجة فحص طفرات جين CEBPA، وهل النتيجة مضمونة الدقة؟

إجابة مختصرة: تستغرق نتيجة فحص الكشف عن طفرات جين CEBPA مدة 10 أيام عمل كحد أقصى، ويتم إصدار التقرير النهائي بعد تأكيد التسلسل الجيني ثنائي الاتجاه لضمان دقة تشخيصية تبلغ 99.9%. المختبر معتمد دولياً بشهادة ISO 9001:2015 (رقم الشهادة: INT/EGQ/2509DA/3139)، وتُجرى جميع التحاليل وفق بروتوكولات هيئة الصحة بدبي لعام 2026، مع إمكانية التواصل المباشر مع الأطباء الاستشاريين لتفسير النتائج سريرياً.